Cargando…

GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases

N-methyl-D-aspartate receptors (NMDARs) are ion channels that respond to the neurotransmitter glutamate, playing a crucial role in the permeability of calcium ions and excitatory neurotransmission in the central nervous system (CNS). Composed of various subunits, NMDARs are predominantly formed by t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladagu, Amany Digal, Olopade, Funmilayo Eniola, Adejare, Adeboye, Olopade, James Olukayode
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674917/
https://www.ncbi.nlm.nih.gov/pubmed/38004401
http://dx.doi.org/10.3390/ph16111535
_version_ 1785140941367017472
author Ladagu, Amany Digal
Olopade, Funmilayo Eniola
Adejare, Adeboye
Olopade, James Olukayode
author_facet Ladagu, Amany Digal
Olopade, Funmilayo Eniola
Adejare, Adeboye
Olopade, James Olukayode
author_sort Ladagu, Amany Digal
collection PubMed
description N-methyl-D-aspartate receptors (NMDARs) are ion channels that respond to the neurotransmitter glutamate, playing a crucial role in the permeability of calcium ions and excitatory neurotransmission in the central nervous system (CNS). Composed of various subunits, NMDARs are predominantly formed by two obligatory GluN1 subunits (with eight splice variants) along with regulatory subunits GluN2 (GluN2A-2D) and GluN3 (GluN3A-B). They are widely distributed throughout the CNS and are involved in essential functions such as synaptic transmission, learning, memory, plasticity, and excitotoxicity. The presence of GluN2A and GluN2B subunits is particularly important for cognitive processes and has been strongly implicated in neurodegenerative diseases like Parkinson’s disease and Alzheimer’s disease. Understanding the roles of GluN2A and GluN2B NMDARs in neuropathologies provides valuable insights into the underlying causes and complexities of major nervous system disorders. This knowledge is vital for the development of selective antagonists targeting GluN2A and GluN2B subunits using pharmacological and molecular methods. Such antagonists represent a promising class of NMDA receptor inhibitors that have the potential to be developed into neuroprotective drugs with optimal therapeutic profiles.
format Online
Article
Text
id pubmed-10674917
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106749172023-10-30 GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases Ladagu, Amany Digal Olopade, Funmilayo Eniola Adejare, Adeboye Olopade, James Olukayode Pharmaceuticals (Basel) Review N-methyl-D-aspartate receptors (NMDARs) are ion channels that respond to the neurotransmitter glutamate, playing a crucial role in the permeability of calcium ions and excitatory neurotransmission in the central nervous system (CNS). Composed of various subunits, NMDARs are predominantly formed by two obligatory GluN1 subunits (with eight splice variants) along with regulatory subunits GluN2 (GluN2A-2D) and GluN3 (GluN3A-B). They are widely distributed throughout the CNS and are involved in essential functions such as synaptic transmission, learning, memory, plasticity, and excitotoxicity. The presence of GluN2A and GluN2B subunits is particularly important for cognitive processes and has been strongly implicated in neurodegenerative diseases like Parkinson’s disease and Alzheimer’s disease. Understanding the roles of GluN2A and GluN2B NMDARs in neuropathologies provides valuable insights into the underlying causes and complexities of major nervous system disorders. This knowledge is vital for the development of selective antagonists targeting GluN2A and GluN2B subunits using pharmacological and molecular methods. Such antagonists represent a promising class of NMDA receptor inhibitors that have the potential to be developed into neuroprotective drugs with optimal therapeutic profiles. MDPI 2023-10-30 /pmc/articles/PMC10674917/ /pubmed/38004401 http://dx.doi.org/10.3390/ph16111535 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ladagu, Amany Digal
Olopade, Funmilayo Eniola
Adejare, Adeboye
Olopade, James Olukayode
GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
title GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
title_full GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
title_fullStr GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
title_full_unstemmed GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
title_short GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases
title_sort glun2a and glun2b n-methyl-d-aspartate receptor (nmdars) subunits: their roles and therapeutic antagonists in neurological diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674917/
https://www.ncbi.nlm.nih.gov/pubmed/38004401
http://dx.doi.org/10.3390/ph16111535
work_keys_str_mv AT ladaguamanydigal glun2aandglun2bnmethyldaspartatereceptornmdarssubunitstheirrolesandtherapeuticantagonistsinneurologicaldiseases
AT olopadefunmilayoeniola glun2aandglun2bnmethyldaspartatereceptornmdarssubunitstheirrolesandtherapeuticantagonistsinneurologicaldiseases
AT adejareadeboye glun2aandglun2bnmethyldaspartatereceptornmdarssubunitstheirrolesandtherapeuticantagonistsinneurologicaldiseases
AT olopadejamesolukayode glun2aandglun2bnmethyldaspartatereceptornmdarssubunitstheirrolesandtherapeuticantagonistsinneurologicaldiseases